Clindamycin
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CLEOCIN | — | 1995-10-05 – 1998-03-02 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | CLEOCIN HYDROCHLORIDE | — | 1970-05-22 – 1988-04-14 | fda.gov ↗ |
| Approved | US (FDA) | CLEOCIN HYDROCHLORIDE | — | 1970-02-22 | fda.gov ↗ |
Trials 130 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05582434 | Feb 2024 → Jun 2025 overdue | acne | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04980170 | Nov 2021 → Mar 2022 | — | Jordan University Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT00503542 | Feb 2007 → Feb 2008 | vaginitis | Agency for Healthcare Research and Quality (AHRQ) | Completed | No outcome recorded |
| Phase 119 trials | ||||||
| Phase 1 | NCT06673641 | May → Sep 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05354050 | Nov 2020 | bacterial vaginosis | Daré Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04198129 | Oct 2020 → Jan 2022 | infectious disease | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 1 | NCT04321070 | Sep → Dec 2019 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04134273 | Mar → Sep 2019 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03653403 | Aug 2018 → Jun 2019 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05367479 | Jul 2018 → Jan 2020 | hypertensive disorder, morbid obesity | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT02475876 | Nov 2015 → Aug 2018 | gram-positive bacterial infections | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 1 | NCT02545452 | Sep 2015 → Mar 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02578043 | Apr → Aug 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01728363 | Jan 2013 → May 2015 | infectious disease | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 1 | NCT01769235 | Nov 2012 → Sep 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01769664 | Sep 2012 → Jun 2013 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01428466 | Nov 2010 → Feb 2011 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01132443 | May → Jun 2010 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01929278 | Dec 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01915758 | Nov 2008 → Feb 2009 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00836056 | Nov 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00836004 | Nov 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07504822 | Apr 2026 → Mar 2027 expected | acne | Yohanes Firmansyah, dr, MH, MM | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04118296 | Oct → Nov 2019 | acne | Sukma Skin Treatment | Completed | No outcome recorded |
| Phase 1/2 | NCT02593383 | Mar 2015 → Jul 2017 | acne | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT00361322 | Apr 2005 → Jan 2006 | acne | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT07267013 | Apr → Jul 2026 overdue | aortic disorder | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05926869 | Aug → Dec 2022 | acne | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 2 | NCT04892706 | Jun 2021 → Sep 2022 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04469075 | Jul 2020 → Jul 2026 overdue | glioblastoma, toxic dermatosis | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04039750 | Jul 2019 → Dec 2026 expected | appendicitis | Prisma Health-Upstate | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2 | NCT03476941 | Apr 2019 → May 2021 overdue | abscess | University of Iowa | Recruiting | No outcome recorded |
| Phase 2 | NCT03257202 | Sep 2017 → Jan 2018 | — | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT03122457 | Jan 2017 → Jul 2018 | actinic keratosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02730962 | Jun 2016 → Jan 2018 | prediabetes syndrome | University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT01361269 | Jun → Sep 2011 | malaria | Zentopharm GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT01464138 | Sep 2010 → Sep 2011 | malaria | Jomaa Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00730028 | Apr 2009 → Feb 2015 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT00713609 | Jun 2008 → Mar 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00217451 | Jun 2002 → Mar 2003 | malaria | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04349410 | Apr → Sep 2020 | COVID-19 | The Camelot Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT00729937 | Apr 2009 → May 2013 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/3 | NCT00823901 | Feb 2009 → Oct 2010 | rosacea | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03033472 | ? → Dec 2017 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT06841003 | Feb 2025 → Mar 2027 expected | abscess, appendicitis | Spaarne Gasthuis | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06336824 | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT05502380 | Sep 2022 → Dec 2024 overdue | bacterial infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05164081 | Jan 2022 → Jan 2026 overdue | periprosthetic joint infection | Umeå University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04067531 | Aug 2020 → Aug 2021 | bacterial infectious disease | Skaraborg Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04370548 | Jun → Nov 2020 | bacterial vaginosis | Daré Bioscience, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03081962 | Feb → Aug 2017 | — | Hospital General Universitario Elche | Unknown | No outcome recorded |
| Phase 3 | NCT02515305 | Jul 2015 → Apr 2016 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02465632 | Apr → Nov 2015 | acne | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT03374176 | Mar 2014 → Jul 2016 | chronic periodontitis, type 2 diabetes mellitus | Centro Universitario de Tonalá | Completed | No outcome recorded |
| Phase 3 | NCT02479971 | Jan 2014 → Jun 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT02210689 | Jan → Oct 2014 | bacterial vaginosis, vaginal discharge, vulvovaginitis | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01792804 | Dec 2013 → Mar 2020 | staphylococcus aureus infection | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 3 | NCT02005666 | Nov 2013 → Sep 2016 | acne | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 3 | NCT02314806 | Jan 2013 → Dec 2014 | breast cancer | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 3 | NCT01788384 | Jul → Dec 2012 | acne | Watson Laboratories, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01796665 | Feb 2012 → Feb 2013 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT01445301 | Sep 2011 → Aug 2012 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01293643 | May 2010 → Jan 2011 | bacterial vaginosis, vulvovaginal candidiasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00889356 | Sep 2009 → Mar 2010 | bacterial vaginosis, candidiasis | Zodiac Produtos Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT00891982 | Apr → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00838812 | Mar 2009 → Jan 2010 | acne | Igefarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00694928 | May 2008 → Nov 2009 | infective vaginitis | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00689117 | Apr 2008 → Apr 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT01867164 | Dec 2007 → Dec 2008 | infective vaginitis | Janssen-Cilag, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00214643 | Jun 2005 → Jul 2006 | malaria | Albert Schweitzer Hospital, Netherlands | Completed | No outcome recorded |
| Phase 3 | NCT00000640 | ? → Sep 1994 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 436 trials | ||||||
| Phase 4 | NCT07561541 | Apr 2026 → Dec 2027 expected | diabetes mellitus | Texas Tech University Health Sciences Center, El Paso | Recruiting | No outcome recorded |
| Phase 4 | NCT07357103 | Mar 2026 → Mar 2029 expected | pneumocystosis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07474194 | Sep 2025 → Apr 2026 overdue | — | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT06494072 | Aug 2024 → May 2028 expected | — | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 4 | NCT05867654 | Jul 2024 → Nov 2025 overdue | osteomyelitis | University of Louisville | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06336629 | Nov 2023 → Jul 2024 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06172010 | Apr 2023 → Mar 2027 expected | periprosthetic joint infection | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05137119 | Feb 2022 → Dec 2028 expected | staphylococcus aureus infection | University of Melbourne | Recruiting | No outcome recorded |
| Phase 4 | NCT04834310 | Apr 2021 → May 2024 | breast disorder, poisoning | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 4 | NCT04035070 | Jan → Jun 2021 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04580472 | Oct 2020 → Sep 2026 expected | — | Carilion Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04573504 | Sep 2020 → Sep 2024 | — | Northwestern University | Unknown | No outcome recorded |
| Phase 4 | NCT03560232 | Jul 2018 → Feb 2020 | — | Mercy Health Ohio | Terminated | No outcome recorded |
| Phase 4 | NCT04516148 | May 2018 → Oct 2020 | skin infection | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03883269 | Mar 2018 → Jun 2019 overdue | acne | Centre for Human Drug Research, Netherlands | Recruiting | No outcome recorded |
| Phase 4 | NCT03478163 | Mar 2018 → May 2021 | endometritis, obstetric disorder | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01899690 | Jun 2016 → Aug 2017 | prosthesis-related infectious disease | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02309346 | Dec 2014 → Dec 2023 | uterine disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT02058628 | Feb → Sep 2014 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01448733 | Jul → Oct 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01585129 | Sep 2010 → Jul 2014 | — | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT01111994 | Nov 2009 → Mar 2010 | acne | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00964223 | Jul → Nov 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00964366 | Jul → Aug 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00926367 | May → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT01047189 | Mar → Oct 2009 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00887484 | Feb → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00671749 | Dec 2007 → Aug 2008 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00841776 | Aug 2007 → Nov 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00807014 | Nov 2006 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00377000 | Nov 2005 → Mar 2006 | acne | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00219570 | Jan → Jun 2005 | acne | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00160394 | Dec 2004 → Aug 2005 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00398658 | Mar 2002 → Dec 2004 | endophthalmitis | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT06702345 | Mar 2025 → Jul 2026 overdue | Clostridium difficile colitis | Leiden University Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07123792 | Jun 2024 → May 2025 | periodontal disorder | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06787885 | May 2024 → May 2026 | pleural empyema | Fayoum University | Completed | No outcome recorded |
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT06068673 | Mar → Dec 2023 | nervous system disorder | Damanhour University | Completed | No outcome recorded |
| — | NCT03779295 | Nov 2018 → Jun 2019 | acneiform dermatitis | West Virginia University | Withdrawn | No outcome recorded |
| — | NCT03742908 | Jun 2018 → Oct 2021 | breast neoplasm | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT04818931 | Apr 2018 → Jun 2019 | breast cancer | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
| — | NCT02196740 | Jun 2013 → Dec 2014 | periapical periodontitis | Lin Jiacheng | Unknown | No outcome recorded |
| — | NCT01722708 | Nov 2012 → Jul 2025 | bacterial vaginosis | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01561703 | Mar 2012 → Dec 2013 | streptococcal sore throat | University of Missouri-Columbia | Completed | No outcome recorded |
| — | NCT01114516 | Mar 2010 → Mar 2013 | cervical incompetence | Northwestern University | Completed | No outcome recorded |
| — | NCT01498744 | Feb 2010 → Feb 2013 | abscess, methicillin-resistant staphylococcus aureus infectious disease | Ann & Robert H Lurie Children's Hospital of Chicago | Terminated | No outcome recorded |
| — | NCT00814905 | Nov 2008 → Jan 2012 | chorioamnionitis | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded |
| — | NCT00002064 | — | HIV infectious disease, cerebral toxoplasmosis | Palo Alto Medical Foundation | Completed | No outcome recorded |
| — | NCT00000674 | ? → Aug 1992 | HIV infectious disease, cerebral toxoplasmosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00000717 | ? → Nov 1991 | HIV infectious disease, pneumocystosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 102 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05849090 Comparator | Mar 2023 → Dec 2024 | infectious disease | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07663838 Comparator | Jun 2026 → Jan 2027 expected | bacterial vaginosis | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02595034 Comparator | Jan → Oct 2015 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01744730 Comparator | Jun 2013 → Aug 2014 | bacterial infectious disease, obesity disorder | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03578965 Background | Jul 2018 → Nov 2021 | low grade vulvar intraepithelial neoplasia, vulvar benign neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT05166746 Comparator | Dec 2017 → Oct 2023 | bacterial vaginosis, female infertility | Peter Humaidan | Unknown | No outcome recorded |
| Phase 2 | NCT03234517 Background | Aug 2016 → Aug 2018 | bacterial vaginosis | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT01874860 Background | Aug 2013 → Jul 2018 | colorectal cancer, head and neck cancer | University of Louisville | Completed | No outcome recorded |
| Phase 2 | NCT01757236 Comparator | Oct 2012 → Apr 2016 | periprosthetic joint infection | University Hospital, Tours | Unknown | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07202091 Background | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06006663 Comparator | Aug → Oct 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05678621 Background | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01994993 Comparator | Dec 2013 → Jan 2017 | — | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 2/3 | NCT01400867 Background | Dec 2011 → May 2014 | primary bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 2/3 | NCT01127880 Comparator | Jul 2005 → Dec 2009 | hemopneumothorax | St. Luke's Hospital, Pennsylvania | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07107477 Comparator | May 2025 → Sep 2027 expected | preterm premature rupture of the membranes | The Central and Eastern European Gynecologic Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT04723940 Comparator | Jan 2021 → Jan 2023 | periprosthetic joint infection | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04194216 Comparator | May 2020 → Dec 2026 expected | nasal disorder | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04104178 Comparator | May 2020 → Sep 2025 | methicillin-resistant staphylococcus aureus infectious disease | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03945357 Comparator | May 2019 → Jan 2023 | — | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 3 | NCT03176134 Comparator | Jan 2019 → Jul 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03615768 Comparator | Aug 2018 → Feb 2020 | acne | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT02814916 Comparator | Mar 2017 → Jan 2024 | methicillin-resistant staphylococcus aureus infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02809131 Comparator | Apr 2016 → Mar 2021 | sick sinus syndrome, systolic heart failure, third-degree atrioventricular block | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02276482 Comparator | Mar 2015 → Sep 2018 | skin disease caused by bacterial infection, skin infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02579161 Comparator | Sep 2014 → Mar 2018 | urolithiasis | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT01915732 Comparator | Apr 2013 → Apr 2014 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01374581 Comparator | May 2012 → Jun 2014 | malaria | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT00911573 Comparator | Aug 2011 → May 2014 | infectious disease, skin disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT01138514 Comparator | Oct 2009 → Oct 2010 | acne | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT00776919 Comparator | Oct 2008 → Sep 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00616330 Comparator | Jan 2008 → Dec 2009 | vulvovaginitis | Lumara Health, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01125410 Comparator | Jan 2007 → Jul 2008 | bacterial vaginosis | Medinova AG | Completed | No outcome recorded |
| Phase 3 | NCT00663286 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00664248 Comparator | Oct 2006 → Aug 2007 | acne | Dow Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00372294 Comparator | Jul 2005 → Aug 2008 | chorioretinitis | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT07392047 Comparator | Feb → Aug 2026 overdue | acne | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06422221 Comparator | Jul 2024 → Jan 2025 | bacterial infectious disease, endocarditis | University of Santiago de Compostela | Unknown | No outcome recorded |
| Phase 4 | NCT05899140 Comparator | Mar 2024 → Mar 2026 overdue | skin infection, staphylococcus aureus infection | Frieder Schaumburg | Recruiting | No outcome recorded |
| Phase 4 | NCT05846399 Comparator | Sep 2023 → Jul 2027 expected | cat-scratch disease | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT05206500 Background | May 2022 → Dec 2028 expected | urinary tract infection | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT04512638 Background | Jan 2021 → Oct 2025 | osteonecrosis of the jaw | Tim Van den Wyngaert | Unknown | No outcome recorded |
| Phase 4 | NCT04502095 Background | Sep 2020 → Mar 2025 | urinary bladder carcinoma, urinary tract infection | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 4 | NCT05268835 Comparator | Feb 2020 → Aug 2022 | impacted teeth, multiple | Oral and Maxillofacial Surgery Clinic, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT03333408 Comparator | Jun 2018 → Dec 2024 | — | Our Lady of the Lake Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03261830 Comparator | Aug 2017 → Mar 2023 | — | Sumit Gupta | Completed | No outcome recorded |
| Phase 4 | NCT02860845 Comparator | Jul 2016 → Oct 2017 | bacterial vaginosis, candidiasis | Laboratorios Ordesa | Completed | No outcome recorded |
| Phase 4 | NCT03080740 Comparator | Jul 2016 → Jul 2017 | bacterial vaginosis | Guangzhou Yipinhong Pharmaceutical CO.,LTD | Unknown | No outcome recorded |
| Phase 4 | NCT02721173 Comparator | Apr → Dec 2016 | acne | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT02557399 Comparator | Oct → Dec 2015 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02731105 Comparator | Feb 2015 → Feb 2017 | acne | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02446782 Background | Jan 2015 → Apr 2016 | empyema, pleurisy | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 4 | NCT02018094 Comparator | Oct 2013 → Mar 2014 | skin infection | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT01876628 Comparator | Oct 2013 → Dec 2015 | cellulitis | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01951768 Comparator | Sep 2013 → Jun 2016 | ulcer of lower limbs | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT01800825 Comparator | Jul 2013 → Apr 2016 | bacterial vaginosis, pregnancy disorder | Christiana Care Health Services | Completed | No outcome recorded |
| Phase 4 | NCT02141217 Comparator | Mar → Dec 2013 | tooth disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01728376 Comparator | Nov 2012 → Jan 2016 | bacterial infectious disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01669980 Background | Oct 2012 → May 2014 | pneumonia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01422785 Comparator | Jul → Dec 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01613092 Comparator | May 2011 → Nov 2013 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01697826 Comparator | Apr → Sep 2011 | infective vaginitis | Dr Bharti Daswani | Completed | No outcome recorded |
| Phase 4 | NCT01231334 Comparator | Aug 2010 → Jun 2011 | acne | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01015638 Comparator | Aug → Sep 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00711802 Comparator | Jul 2008 → Oct 2013 | skin disease caused by bacterial infection | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00636935 Background | Feb 2008 → Aug 2013 | pneumocystosis | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00837213 Comparator | Aug 2007 → Aug 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT01245322 Comparator | Jan 2007 → Oct 2014 | bacterial vaginosis | Skaraborg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00352612 Comparator | Sep 2006 → May 2009 | abscess, folliculitis, staphylococcal infection | Aaron Chen | Completed | No outcome recorded |
| Phase 4 | NCT00642980 Comparator | Apr 2006 → Jun 2011 | pregnancy disorder | University Hospital, Lille | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07032883 Background | Jun 2025 → Feb 2026 overdue | female breast carcinoma | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT06207786 Background | Sep 2024 → May 2029 | epidermal appendage tumor, skin cancer | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT07247851 Comparator | Jan → Jun 2024 | bacterial vaginosis | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| — | NCT05762484 Comparator | Apr 2023 → Dec 2024 | hidradenitis suppurativa | Erasmus Medical Center | Unknown | No outcome recorded |
| — | NCT06174909 Comparator | Nov 2022 → Aug 2023 | — | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT04631185 Background | May 2021 → Dec 2023 | — | The Plastic Surgery Foundation | Completed | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT04438655 Background | May 2019 → Nov 2021 | — | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT04093765 Background | Nov 2018 → Dec 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT03779360 Comparator | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03412071 Comparator | Dec 2017 → Dec 2019 | — | University of Toronto | Unknown | No outcome recorded |
| — | NCT03326661 Comparator | Nov 2017 → Nov 2019 | peritonsillar abscess | Odense University Hospital | Unknown | No outcome recorded |
| — | NCT02674191 Background | May 2016 → Jun 2018 | — | Manal El Namrawy | Unknown | No outcome recorded |
| — | NCT02585141 Background | Oct 2015 → Jun 2020 | anal fistula | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT02054676 Background | Feb 2014 → Apr 2016 | — | Lithuanian University of Health Sciences | Unknown | No outcome recorded |
| — | NCT01945450 Comparator | Jan 2014 → Sep 2016 | endometritis | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01823523 Comparator | Jun 2013 → Oct 2015 | craniofacial and skeletal defects | Atlantic Center for Oral and Maxillofacial Surgery | Unknown | No outcome recorded |
| — | NCT01715610 Comparator | May 2012 → Nov 2015 | peritonsillar abscess | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| — | NCT01619410 Comparator | Jan 2012 → Dec 2016 | abscess, skin disease caused by bacterial infection | University of Chicago | Terminated | No outcome recorded |
| — | NCT01235546 Comparator | May 2011 → Dec 2015 | abscess, endometritis, skin infection | Alan Tita | Completed | No outcome recorded |
| — | NCT01237821 Comparator | Oct 2010 → Aug 2011 | acne | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT01500837 Comparator | Oct 2010 → Oct 2011 | infective arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01155154 Comparator | Feb 2010 → Feb 2012 | — | State University of New York - Downstate Medical Center | Terminated | No outcome recorded |
| — | NCT01063270 Comparator | Feb 2010 → Jul 2011 | hidradenitis suppurativa | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT01052246 Comparator | Oct 2008 → Jun 2009 | acne | Laserklinik Karlsruhe | Completed | No outcome recorded |
| — | NCT01044264 Comparator | Dec 2007 → Sep 2008 | acne | Padagis LLC | Completed | No outcome recorded |
| — | NCT00186082 Comparator | Sep 2003 → Jun 2006 | puerperal infection | Stanford University | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-12 | Organon and Co | Organon and Evvy Announce Collaboration to Expand Access of XACIATO® (clindamycin phosphate) vaginal gel 2%, a Treatment for Bacterial Vaginosis organon.com ↗ |
| 2024-01-10 | Organon and Co | Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older organon.com ↗ |
| 2022-03-31 | Organon and Co | Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV) organon.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 236 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clindamycin | “METHODS: This 16-week, two-center, investigator-blinded, randomized, parallel-group study evaluated the antimicrobial efficacy of clindamycin phosphate 1%/benzoyl peroxide 5%...” PMID 20214175 ↗ Feb 2010224“Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or...” NCT01728376 ↗ “To evaluate the safety and plasma pharmacokinetics (PK) of clindamycin and adapalene in IDP-126 Gel compared with that from Control Gel in subjects with moderate to severe acne...” NCT03653403 ↗ “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours,...” NCT03935828 ↗ “Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the...” NCT03176134 ↗ “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ “Patients will be randomized at the time of surgery to receive intravenous cefazolin or clindamycin (weight-based dosing) as a pre-operative antibiotic within 60 minutes of...” NCT05367479 ↗ “Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.” NCT02276482 ↗ “All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.” NCT04834310 ↗ “One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.” NCT01867164 ↗ “Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.” NCT01876628 ↗ “It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle.” NCT06174909 ↗ “One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage” NCT01561703 ↗ “A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral.” NCT07123792 ↗ “Clindamycin phosphate (CLIN) 1.2%/adapalene (ADAP) 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB) is the only triple-combination topical approved for acne.” PMID 40377868 ↗ May 2025 “Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.” NCT01585129 ↗ “Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.” NCT05678621 ↗ “NB: Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin.” NCT07202091 ↗ “gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily” NCT00160394 ↗ “Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin.” NCT07202052 ↗ “The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.” NCT00711802 ↗ “Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.” NCT02054676 ↗ “Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%” NCT04118296 ↗ “Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections” NCT01728363 ↗ “Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) With Healthy Japanese Male and Female Subjects” NCT01428466 ↗ “If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.” NCT02446782 ↗ “Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks” NCT00689117 ↗ “Vancomycin 1g IV every 12 h or Clindamycin 600-900g IV every 8h taking antibiotic sensitivity into account.” NCT07107477 ↗ “Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).” NCT04093765 ↗ “antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone)” NCT00636935 ↗ “Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin” NCT01613092 ↗ “Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours” NCT05268835 ↗ “Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.” NCT00891982 ↗ “intraperitoneal irrigation with clindamycin (600mg) and gentamicin (240 mg) solution” NCT03081962 ↗ “Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.” PMID 25785967 ↗ Mar 2015 “antibiotic irrigation using gentamicin, clindamycin and suction during the surgery” NCT04039750 ↗ “or vancomycin 1 g or clindamycin 600 mg in case of intolerance to cephalosporins” NCT05502380 ↗ “Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.” NCT00186082 ↗ “intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole” NCT01697826 ↗ “In case of allergy to cefazolin, intravenous clindamycin will be prescribed.” NCT04631185 ↗ “Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine” NCT02366884 ↗ “single post-operative dose administration of Unasyn 3g or Clindamycin 600mg” NCT04198129 ↗ “Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg” NCT01445301 ↗ “Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h” NCT01951768 ↗ “100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days” NCT02545452 ↗ “CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).” NCT02557399 ↗ “If patient has a penicillin allergy then clindamycin will be used.” NCT03578965 ↗ “cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy” NCT04818931 ↗ “Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks” NCT01237821 ↗ “If allergic to ampicillin /cephalosporins clindamycin IV” NCT07032883 ↗ “clindamycin phosphate \[equivalent to 1% clindamycin\]” NCT00807014 ↗ “single dose of Clindamycin hydrochloride 600 mg PO” NCT04580472 ↗ “standard of care (cephazolin or clindamycin)” NCT01235546 ↗ “clindamycin, ciprofloxacin and metronidazole” NCT06006663 ↗ “Clindamycin 600 mg + Gentamycin 2 mg/kg.” NCT04438655 ↗ “Clindamycin Phosphate topical gel 1%” NCT04134273 ↗ “clindamycin-retinoid combination” NCT07504822 ↗ “topical antibiotic (clindamycin)” NCT00332163 ↗ “Clindamycin 1%, Tretinoin 0,025%” NCT02731105 ↗ “* Clindamycin : 600-900mg/8h” NCT05074147 ↗ “PO clindamycin 13 mg/kg/dose” NCT01669980 ↗ “Clindamycin 300mg tid PO” NCT04512638 ↗ “2% Clindamycin 100 MG” NCT05354050 ↗ “Clindamycin” NCT06207786 ↗ “Clindamycin” NCT05846399 ↗ “Clindamycin” NCT02099240 ↗ “Clindamycin” NCT04751500 ↗ “Clindamycin” NCT05206500 ↗ |
| Known as | CDP | “OBJECTIVE: The aim of this study was to compare the efficacy and safety of clindamycin (1%) and benzoyl peroxide (5%) (CDP/BPO) gel once daily vs. clindamycin (1%) (CDP)...” PMID 27075705 ↗ Apr 2016 |
| Known as | CLDM | “CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).” NCT02557399 ↗ |
| Known as | Cleocin | “Cleocin is a trade name and the generic name is clindamycin.” NCT04198129 ↗1“Clindamycin, (Cleocin, Clindesse)” NCT05849090 ↗ |
| Known as | cleocin (clindamycin) | “cleocin (clindamycin)” NCT04194216 ↗ |
| Known as | Cleocin T | “Multiple topical applications of Cleocin T (clindamycin phosphate at a concentration equivalent to 10mg/mL) resulted in clindamycin serum levels ranging from 0 to 3 ng/mL.” NCT01132443 ↗ |
| Known as | CLINDA | “clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)” NCT00730028 ↗ |
| Known as | Clindagel | “Topical application of Clindagel (clindamycin phosphate 1% gel) equivalent to 3 to 12 grams once daily for 5 days resulted in peak plasma clindamycin concentrations that were...” NCT01132443 ↗ |
| Known as | Clindamycin (Clindesse) | “Clindamycin (Clindesse)” NCT02168816 ↗ |
| Known as | Clindamycin generic; Brand Cleocin | “Clindamycin generic; Brand Cleocin” NCT01728363 ↗ |
| Known as | Clindamycin palmitate hydrochloride | “Clindamycin palmitate hydrochloride dispersible tablet” NCT03080740 ↗ |
| Known as | Clindamycin Phosphate | “Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel” NCT03122457 ↗11“Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.” NCT00838812 ↗ “1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide” NCT01915732 ↗ “Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks” NCT03615768 ↗ “clindamycin phosphate \[equivalent to 1% clindamycin\]” NCT00807014 ↗ “Clindamycin phosphate 6 mg/1ml for injection” NCT03476941 ↗ “Drug: Clindamycin Phosphate” NCT04469075 ↗ |
| Known as | Clindamycin/Cleocin Pediatric | “Clindamycin/Cleocin Pediatric” NCT01561703 ↗ |
| Known as | Clindesse | “Reference Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate...” NCT02210689 ↗1“Clindamycin, (Cleocin, Clindesse)” NCT05849090 ↗ |
| Known as | CLM | “AIMS: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV).” PMID 22205034 ↗ Dec 2011 |
| Known as | CLN | “clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)” NCT01132443 ↗ |
| Known as | Dalacin 300 mg | “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ |
| Known as | Dalacin C | “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗2“Augmentin™ (amoxicillin + clavulanic acid) from GSK and Dalacin-C (clindamycin) from Pfizer will be used as study treatments.” NCT02141217 ↗ “Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours” NCT05268835 ↗ |
| Known as | Dalacin T Gel | “Dalacin T Gel (clindamycin phosphate gel)” NCT00219570 ↗ |
| Known as | Dalacin vaginal cream 2% | “women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days...” NCT01245322 ↗ |
| Known as | DARE-BV1 | “This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC...” NCT04370548 ↗1“Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).” NCT05354050 ↗ |
| Known as | XACIATO | “On March 31, 2022, Daré Bioscience, Inc and Organon & Co entered into an exclusive license agreement in which Organon obtained exclusive worldwide rights to develop,...” PMID 37098453 ↗ Apr 2023 |
| Action | Inhibit | “Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes.” NCT03779360 ↗ |
| Route | Oral | “two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of...” NCT00000640 ↗ |